TY - JOUR
T1 - Native thrombopoietin
T2 - Structure and function
AU - Kato, Takashi
AU - Matsumoto, Atsushi
AU - Ogami, Kinya
AU - Tahara, Tomoyuki
AU - Morita, Haruhiko
AU - Miyazaki, Hiroshi
PY - 1998
Y1 - 1998
N2 - Thrombopoietin (TPO), the c-Mpl ligand, is produced constitutively in liver and other organs, circulates in the bloodstream, and is delivered to bone marrow, where it stimulates the early development of multiple hematopoietic lineages and megakaryocytopoiesis. The concentration of TPO in blood is regulated by c-Mpl mass on platelets and megakaryocytes. In addition to regulation by the number of TPO molecules, including the possible modulation of TPO mRNA abundance in bone marrow, megakaryocytopoiesis and platelet production may be regulated as a result of modulation of TPO activity by proteolytic processing that generates truncated forms of the molecule. Characterization of TPO partially purified from human plasma, however, revealed that the full-length molecule was the predominant form in the blood of both normal individuals and thrombocytopenic patients, although small amounts of truncated species were detected. Thus, truncation of TPO, at least that in the circulation examined, does not appear to contribute to the direct regulation of platelet production in response to increased demand. Given that native TPO isolated from the plasma of thrombocytopenic animals comprises truncated forms, the truncation of TPO is likely of physiological importance in the life history of this molecule.
AB - Thrombopoietin (TPO), the c-Mpl ligand, is produced constitutively in liver and other organs, circulates in the bloodstream, and is delivered to bone marrow, where it stimulates the early development of multiple hematopoietic lineages and megakaryocytopoiesis. The concentration of TPO in blood is regulated by c-Mpl mass on platelets and megakaryocytes. In addition to regulation by the number of TPO molecules, including the possible modulation of TPO mRNA abundance in bone marrow, megakaryocytopoiesis and platelet production may be regulated as a result of modulation of TPO activity by proteolytic processing that generates truncated forms of the molecule. Characterization of TPO partially purified from human plasma, however, revealed that the full-length molecule was the predominant form in the blood of both normal individuals and thrombocytopenic patients, although small amounts of truncated species were detected. Thus, truncation of TPO, at least that in the circulation examined, does not appear to contribute to the direct regulation of platelet production in response to increased demand. Given that native TPO isolated from the plasma of thrombocytopenic animals comprises truncated forms, the truncation of TPO is likely of physiological importance in the life history of this molecule.
KW - ELISA
KW - Native thrombopoietin
KW - Posttranslational processing
KW - Proteolysis
KW - Thrombocytopenia
KW - Thrombopoietin
KW - Truncation
UR - http://www.scopus.com/inward/record.url?scp=0031691754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031691754&partnerID=8YFLogxK
U2 - 10.1002/stem.160322
DO - 10.1002/stem.160322
M3 - Article
C2 - 9766811
AN - SCOPUS:0031691754
SN - 1066-5099
VL - 16
SP - 322
EP - 328
JO - STEM CELLS
JF - STEM CELLS
IS - 5
ER -